Sign In
Buy GRTX
$0.100
-0.0010 (-0.99%)
At Close: Jun 03, 2026
Galera Therapeutics (NASDAQ:GRTX) Rating Lowered to Hold at Zacks Investment Research
06:04am, Friday, 17'th Apr 2020
Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Gal
Galera Therapeutics Appoints Linda B. West to Board of Directors
12:00pm, Thursday, 02'nd Apr 2020
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
11:00am, Tuesday, 10'th Mar 2020
- Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer.
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
MALVERN, Pa., Feb. 24, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
01:00pm, Wednesday, 19'th Feb 2020
MALVERN, Pa., Feb. 19, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
3 “Strong Buy” Healthcare Stocks That Can Double in 2020
01:00pm, Tuesday, 17'th Dec 2019
Unphased by some risk? If the answer is yes, then healthcare stocks might be the way to go. These names tend to be more volatile in nature as a single catalyst like trial data or a verdict from the FD
Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
12:00pm, Tuesday, 10'th Dec 2019
- Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck.
Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology
10:18pm, Thursday, 05'th Dec 2019
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
Analysts: Galera Has Novel Pipeline For Radiation Oncology Market, Commercialization Remains Headwind
06:10pm, Monday, 02'nd Dec 2019
Galera Therapeutics Inc (NASDAQ: GRTX ), a biopharma company working on novel therapeutics for transforming radiotherapy treatment in cancer, recently IPO'd, offering 5 million shares at $12 apiece. F
Galera Therapeutics Announces Pricing of Initial Public Offering
12:26am, Thursday, 07'th Nov 2019
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to
